385 related articles for article (PubMed ID: 34809825)
1. IgG N-glycans.
Liu S; Liu X
Adv Clin Chem; 2021; 105():1-47. PubMed ID: 34809825
[TBL] [Abstract][Full Text] [Related]
2. Changes of IgG
Trzos S; Link-Lenczowski P; Sokołowski G; Pocheć E
Front Immunol; 2022; 13():841710. PubMed ID: 35370997
[TBL] [Abstract][Full Text] [Related]
3. Metabolic control of recombinant monoclonal antibody N-glycosylation in GS-NS0 cells.
Hills AE; Patel A; Boyd P; James DC
Biotechnol Bioeng; 2001 Oct; 75(2):239-51. PubMed ID: 11536148
[TBL] [Abstract][Full Text] [Related]
4. Immunoglobulin G (IgG) Fab glycosylation analysis using a new mass spectrometric high-throughput profiling method reveals pregnancy-associated changes.
Bondt A; Rombouts Y; Selman MH; Hensbergen PJ; Reiding KR; Hazes JM; Dolhain RJ; Wuhrer M
Mol Cell Proteomics; 2014 Nov; 13(11):3029-39. PubMed ID: 25004930
[TBL] [Abstract][Full Text] [Related]
5. Regulation of antibody effector functions through IgG Fc N-glycosylation.
Quast I; Peschke B; Lünemann JD
Cell Mol Life Sci; 2017 Mar; 74(5):837-847. PubMed ID: 27639381
[TBL] [Abstract][Full Text] [Related]
6. The glycosylation and structure of human serum IgA1, Fab, and Fc regions and the role of N-glycosylation on Fcα receptor interactions.
Mattu TS; Pleass RJ; Willis AC; Kilian M; Wormald MR; Lellouch AC; Rudd PM; Woof JM; Dwek RA
J Biol Chem; 1998 Jan; 273(4):2260-72. PubMed ID: 9442070
[TBL] [Abstract][Full Text] [Related]
7. Modulating IgG effector function by Fc glycan engineering.
Li T; DiLillo DJ; Bournazos S; Giddens JP; Ravetch JV; Wang LX
Proc Natl Acad Sci U S A; 2017 Mar; 114(13):3485-3490. PubMed ID: 28289219
[TBL] [Abstract][Full Text] [Related]
8. Differences in IgG Fc Glycosylation Are Associated with Outcome of Pediatric Meningococcal Sepsis.
de Haan N; Boeddha NP; Ekinci E; Reiding KR; Emonts M; Hazelzet JA; Wuhrer M; Driessen GJ
mBio; 2018 Jun; 9(3):. PubMed ID: 29921663
[TBL] [Abstract][Full Text] [Related]
9. Immunoglobulin G Fc N-glycan profiling in patients with gastric cancer by LC-ESI-MS: relation to tumor progression and survival.
Kodar K; Stadlmann J; Klaamas K; Sergeyev B; Kurtenkov O
Glycoconj J; 2012 Jan; 29(1):57-66. PubMed ID: 22179780
[TBL] [Abstract][Full Text] [Related]
10. Fc Glycosylation Characterization of Human Immunoglobulins G Using Immunocapture and LC-MS.
Helali Y; Sharma S; Vandeput M; Welba D; Van Antwerpen P; Marchant A; Delporte C
Methods Mol Biol; 2021; 2271():57-71. PubMed ID: 33907999
[TBL] [Abstract][Full Text] [Related]
11. IgG glycosylation analysis.
Huhn C; Selman MH; Ruhaak LR; Deelder AM; Wuhrer M
Proteomics; 2009 Feb; 9(4):882-913. PubMed ID: 19212958
[TBL] [Abstract][Full Text] [Related]
12. Immunoglobulin G Fragment Crystallizable Glycosylation After Hematopoietic Stem Cell Transplantation Is Dissimilar to Donor Profiles.
de Haan N; van Tol MJD; Driessen GJ; Wuhrer M; Lankester AC
Front Immunol; 2018; 9():1238. PubMed ID: 29915589
[TBL] [Abstract][Full Text] [Related]
13. CD16a with oligomannose-type
Subedi GP; Barb AW
J Biol Chem; 2018 Oct; 293(43):16842-16850. PubMed ID: 30213862
[TBL] [Abstract][Full Text] [Related]
14. Influence of N-glycosylation on effector functions and thermal stability of glycoengineered IgG1 monoclonal antibody with homogeneous glycoforms.
Wada R; Matsui M; Kawasaki N
MAbs; 2019; 11(2):350-372. PubMed ID: 30466347
[TBL] [Abstract][Full Text] [Related]
15. Variations in oligosaccharide-protein interactions in immunoglobulin G determine the site-specific glycosylation profiles and modulate the dynamic motion of the Fc oligosaccharides.
Wormald MR; Rudd PM; Harvey DJ; Chang SC; Scragg IG; Dwek RA
Biochemistry; 1997 Feb; 36(6):1370-80. PubMed ID: 9063885
[TBL] [Abstract][Full Text] [Related]
16. Clinical severity of visceral leishmaniasis is associated with changes in immunoglobulin g fc N-glycosylation.
Gardinassi LG; Dotz V; Hipgrave Ederveen A; de Almeida RP; Nery Costa CH; Costa DL; de Jesus AR; Mayboroda OA; Garcia GR; Wuhrer M; de Miranda Santos IK
mBio; 2014 Dec; 5(6):e01844. PubMed ID: 25467439
[TBL] [Abstract][Full Text] [Related]
17. Harnessing IgG Fc glycosylation for clinical benefit.
Archer EJ; Gonzalez JC; Ghosh D; Mellins ED; Wang TT
Curr Opin Immunol; 2022 Aug; 77():102231. PubMed ID: 35797920
[TBL] [Abstract][Full Text] [Related]
18. IgG Fc N-glycosylation: Alterations in neurologic diseases and potential therapeutic target?
Kronimus Y; Dodel R; Galuska SP; Neumann S
J Autoimmun; 2019 Jan; 96():14-23. PubMed ID: 30360925
[TBL] [Abstract][Full Text] [Related]
19. Restricted processing of CD16a/Fc γ receptor IIIa
Patel KR; Roberts JT; Subedi GP; Barb AW
J Biol Chem; 2018 Mar; 293(10):3477-3489. PubMed ID: 29330305
[TBL] [Abstract][Full Text] [Related]
20. Effects of terminal galactose residues in mannose α1-6 arm of Fc-glycan on the effector functions of therapeutic monoclonal antibodies.
Aoyama M; Hashii N; Tsukimura W; Osumi K; Harazono A; Tada M; Kiyoshi M; Matsuda A; Ishii-Watabe A
MAbs; 2019 Jul; 11(5):826-836. PubMed ID: 30990348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
